Amicus Therapeutics, Inc.FOLDNASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+25.7%
5Y CAGR+19.8%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+25.7%/yr
vs +27.9%/yr prior
5Y CAGR
+19.8%/yr
Recent acceleration
Acceleration
-2.2pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $76.70M | +44.9% |
| 2024 | $52.94M | +41.8% |
| 2023 | $37.33M | -3.3% |
| 2022 | $38.60M | +12.0% |
| 2021 | $34.47M | +11.0% |
| 2020 | $31.04M | +41.3% |
| 2019 | $21.96M | +52.5% |
| 2018 | $14.40M | +131.0% |
| 2017 | $6.24M | +648.6% |
| 2016 | $833000.00 | - |